Repare Therapeutics Inc. - Common Shares (NQ:RPTX)

2.650 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Repare Therapeutics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >

The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug ↗

October 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In...

Via Benzinga

Repare Therapeutics Announces Pricing of Upsized Offering of Common Shares

October 27, 2021

From Repare Therapeutics Inc.

Via Business Wire

Repare Therapeutics Announces Proposed Public Offering of Common Shares

October 27, 2021

From Repare Therapeutics Inc.

Via Business Wire

Repare Therapeutics to Participate at the H.C. Wainwright 2nd Annual Precision Oncology Conference

October 18, 2021

From Repare Therapeutics Inc.

Via Business Wire

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology ↗

October 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:...

Via Benzinga

Repare Therapeutics Reveals Early Efficacy Data From Lead Program In Solid Tumor Setting ↗

October 11, 2021

Repare Therapeutics Inc (NASDAQ: RPTX) announced the presentation of preliminary Phase 1 monotherapy data from its Phase 1/2 TRESR trial of RP-3500 for solid...

Via Benzinga

Repare Therapeutics Presents Preliminary Phase 1 Monotherapy Clinical Data from the Ongoing First-in-Human Phase 1/2 TRESR Study of RP-3500 in Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 08, 2021

From Repare Therapeutics Inc.

Via Business Wire

28 Stocks Moving In Friday's Mid-Day Session ↗

October 08, 2021

Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares climbed 60.8% to $31.51. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for anti-neutrophil...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

October 08, 2021

Gainers ChemoCentryx (NASDAQ:CCXI) shares rose 77.65% to $34.82 during Friday's pre-market session. The company's market cap stands at $2.4 billion. eFFECTOR...

Via Benzinga

45 Biggest Movers From Yesterday ↗

October 08, 2021

Gainers Camber Energy, Inc.. (NYSE: CEI) shares surged 95.9% to close at $1.78 on Thursday after dipping over 40% on Wednesday. Camber Energy filed amended 8K showing financial...

Via Benzinga

Repare Therapeutics Issues Statement Regarding Inadvertent Issuance of Phase 1/2 TRESR RP-3500 Clinical Trial Abstract by the AACR-NCI-EORTC Virtual International Conference

October 07, 2021

From Repare Therapeutics, Inc.

Via Business Wire

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs ↗

October 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...

Via Benzinga

The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs, And More ↗

October 03, 2021

Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Here are the key catalysts that could move stocks in the unfolding...

Via Talk Markets

The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More ↗

October 03, 2021

Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co...

Via Benzinga

Repare Therapeutics to Present Initial Data from the Phase 1/2 TRESR RP-3500 Clinical Trial at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

September 30, 2021

From Repare Therapeutics Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021 ↗

September 23, 2021

Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ:

Via Benzinga

Repare Therapeutics Appoints Thomas Civik to Its Board and as New Chairman

September 07, 2021

From Repare Therapeutics Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2021 ↗

September 13, 2021

Upgrades For Bank of America Corp (NYSE:

Via Benzinga

Repare Therapeutics to Participate at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference

September 02, 2021

From Repare Therapeutics Inc.

Via Business Wire

Repare Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results

August 12, 2021

From Repare Therapeutics Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2021 ↗

June 28, 2021

Upgrades For Toll Brothers Inc (NYSE:

Via Benzinga

Repare Therapeutics to Participate at the 42nd Annual Goldman Sachs Virtual Global Healthcare Conference

June 02, 2021

From Repare Therapeutics Inc.

Via Business Wire

Cathie Wood Buys $26M Disney Shares And Sells $13M In Netflix: What You Need To Know ↗

May 16, 2021

Cathie Wood-led Ark Investment Management on Friday bought 150,556 shares, worth about $26.15 million, in Walt Disney Co (NYSE: DIS), marking its debut in the media and...

Via Benzinga

Repare Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results

May 13, 2021

From Repare Therapeutics Inc.

Via Business Wire

Cathie Wood Sheds $33.6M Alibaba Shares On Earnings Day ↗

May 14, 2021

Cathie Wood-led Ark Investment Management on Thursday shed 162,840 shares, worth about $33.6 million, in Alibaba Group Holding (NYSE: BABA) after the company posted its first...

Via Benzinga

Cathie Wood Loads Up More On Peloton, Skillz, Teladoc On The Dip ↗

May 06, 2021

Cathie Wood-led Ark Investment Management snapped up over 3 million shares, worth about $48.53 million, in Skillz Inc (NYSE: SKLZ) on Wednesday. SKLZ shares closed 9% lower...

Via Benzinga

Cathie Wood Piles Up Palantir For Third Day In A Row, Adding $39M Worth Of Shares ↗

May 12, 2021

Cathie Wood-led Ark Investment Management on Wednesday snapped up 2.07 million shares, worth about $39 million, in Palantir Technologies Inc (NYSE: PLTR), on a day the...

Via Benzinga

Cathie Wood Loads Up $57M In Palantir As Stock Stages Reversal On Q1 Earnings Beat ↗

May 12, 2021

Cathie Wood-led Ark Investment Management on Tuesday snapped up 2.8 million shares, worth about $56.7 million, in Palantir Technologies Inc (NYSE: PLTR) after the data analytics...

Via Benzinga

Cathie Wood Cuts Apple Stake By 30% And Buys Coinbase, DraftKings ↗

May 10, 2021

Cathie Wood-led Ark Investment Management shed more shares of Apple Inc (NASDAQ:

Via Benzinga

Cathie Wood Slashes Apple Stake To Half — Also Trims Google, Fastly: What You Need To Know ↗

May 07, 2021

Cathie Wood-led Ark Investment Management nearly halved the Apple Inc (NASDAQ: AAPL) stake in the ARK Fintech Innovation ETF (NYSE: ARKF) on Thursday. ARKF shed 298,505 Apple...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.